Search Results
Your search for ,WHo matches 20675 pages
Showing 8351 - 8400FDA Pipeline: Breakthrough Therapy for NSCLC With Specific Mutation, Approval of Test for Cervical Cancer, and More
Over the past week, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to a bispecific antibody for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations; granted approval to a test for human...
Colorectal Cancer Statistics 2020 Published
The burden of colorectal cancer is shifting to younger individuals as incidence increases in young adults and declines in older age groups, according to Colorectal Cancer Statistics 2020. The median age of diagnosis dropped from 72 in 2001–2002 to 66 in 2015–2016. This finding and other data were...
Addition of Venetoclax to Cytarabine in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
In a phase I trial reported in The Lancet Oncology, Karol et al found that the combination of the BCL2 inhibitor venetoclax and the chemotherapeutic agent cytarabine with or without idarubicin produced responses in pediatric patients with relapsed or refractory acute myeloid leukemia. As noted by...
Evaluation of Genetic Testing in NCCN Criteria for Women With Breast Cancer
In a single-institution study reported in the Journal of Clinical Oncology, Yadav et al found that many women with breast cancer with germline pathogenic genetic variants do not qualify for genetic testing on current National Comprehensive Cancer Network® (NCCN®) hereditary testing criteria....
Conventionally Fractionated vs Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer: Long-Term Update
As reported in the Journal of Clinical Oncology by Avkshtol et al, the 10-year update of a single-center trial has confirmed the primary analysis of the study, showing no superiority in 5-year biochemical and/or clinical disease failure rate with moderate hypofractionated intensity-modulated...
Pembrolizumab Plus Radiotherapy Worthy of Further Study in Locally Advanced Squamous Cell Head and Neck Cancer
The combination of the checkpoint inhibitor pembrolizumab and definitive radiation therapy appears to be a safe and feasible option for patients with locally advanced head and neck cancer who are not eligible for cisplatin, according to data presented at the 2020 Multidisciplinary Head and Neck...
Survival in Patients With Pancreatic Cancer Receiving Molecularly Matched Therapies
In a retrospective study reported in The Lancet Oncology, Michael J. Pishvaian, MD, and colleagues found that overall survival was better in patients with pancreatic cancer with actionable molecular alterations who received matched therapies compared with those who received only unmatched therapies ...
Bendamustine/Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis
In a phase II trial reported in the Journal of Clinical Oncology, Suzanne Lentzsch, MD, PhD, and colleagues found that the combination of bendamustine and dexamethasone showed activity in patients with relapsed/refractory systemic light-chain amyloidosis. As stated by the investigators, there...
Preoperative Letrozole for Postmenopausal Patients With Estrogen Receptor–Positive DCIS
In the phase II CALGB 40903/Alliance trial reported in the Journal of Clinical Oncology, E. Shelley Hwang MD, MPH, and colleagues found that preoperative letrozole was associated with beneficial imaging and biomarker changes in postmenopausal women with estrogen receptor (ER)-positive ductal...
HAPLO2019: Advances in Haploidentical Transplantation and Other Novel Cellular Therapies
Now in its seventh year, the Haploidentical Transplant Symposium (HAPLO) continues to explore advances in haploidentical and other novel cellular therapies. The most recent of these meetings—HAPLO2019—met in Orlando, Florida, 2 days before the start of the 2019 American Society of Hematology (ASH)...
Expert Point of View: Daniel V.T. Catenacci, MD
Daniel V.T. Catenacci, MD, of the University of Chicago Medical Center and Biological Sciences, emphasized the value of the patient having microsatellite instability–high (MSI-H) status as a biomarker for immunotherapy. The analysis by Chao et al “highlights how well patients with MSI-H tumors do,...
Survival Benefits Achieved With Pembrolizumab in MSI-H and CPS ≥ 10 Gastric/Gastroesophageal Junction Cancer
Post hoc subanalyses of three KEYNOTE trials established the survival benefit of pembrolizumab in advanced gastric/gastroesophageal junction cancer with microsatellite instability–high (MSI-H) tumors or a programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥ 10 (ie, the number of...
Ho-166 Radioembolization After Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor Liver Metastases
In a single-center Dutch phase II trial reported in The Lancet Oncology, Braat et al found that holmium Ho-166 radioembolization produced responses in patients with neuroendocrine tumor liver metastases who had received peptide receptor radionuclide therapy with lutetium Lu-177 dotatate. Study...
Receipt of Adjuvant vs Neoadjuvant Chemotherapy and Start of Treatment in Patients With Breast Cancer
Research published by Melchior et al in Cancer Medicine has indicated that starting chemotherapy before surgery does not expedite the start or completion of treatment for breast cancer vs performing surgery first. “Increasingly, patients are given [neoadjuvant] chemotherapy…This is done for breast ...
Five-Year Survival for Cancers in Adolescents and Young Adults: 4-Decade Analysis
The 5-year survival rate for adolescents and young adults with cancer has significantly improved from 1975 to 2005 in the United States overall, but this was not the case for all types of cancer, according to a report published by Anderson et al in the Journal of the National Cancer Institute. “We ...
Association of Genomic Prostate Score With Adverse Pathology at Radical Prostatectomy After Initial Active Surveillance
In a study reported in the Journal of Clinical Oncology, Daniel W. Lin, MD, and colleagues found that the 17-gene Oncotype DX Genomic Prostate Score was not associated with the finding of adverse pathology among men with prostate cancer undergoing radical prostatectomy after initial active...
Preoperative Chemoradiotherapy vs Immediate Surgery for Pancreatic Cancer
In the Dutch phase III PREOPANC trial reported in the Journal of Clinical Oncology, Versteijne et al found that preoperative chemoradiotherapy did not improve overall survival vs immediate surgery in patients with resectable and borderline resectable pancreatic cancer. Benefits of preoperative...
FDA Approves Nivolumab/Ipilimumab for Pretreated Patients With Hepatocellular Carcinoma
On March 10, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for patients with hepatocellular carcinoma who have been previously treated with sorafenib. CheckMate 040 Efficacy of the combination was...
Off-the-Shelf Dendritic Vaccine Shows Benefit in Kidney Cancer
Ilixadencel is a cell-based, allogeneic, off-the-shelf product aimed at priming the anticancer immune response when injected intratumorally. The phase II MERECA study evaluated this allogeneic dendritic cell product given with sunitinib in 88 patients with metastatic renal cell carcinoma. The study ...
Study Examines Survival Rates in Pediatric and Young Adult Patients With Colon Cancer
According to research published by Andrea Hayes-Jordan, MD, FACS, and colleagues in the Journal of the American College of Surgeons, children and young adults with colon cancer are more likely to have shorter overall survival and recurrence-free survival than middle-aged adults. In a...
Evaluation of Different Methods of Biopsy for the Diagnosis of Prostate Cancer
In a study reported in The New England Journal of Medicine, Ahdoot et al found that combined use of magnetic resonance imaging (MRI)-targeted biopsy and 12-core systematic prostate biopsy led to enhanced detection of prostate cancers vs either approach alone in men with MRI-visible prostate...
Prognostic Value of Teratoma in Metastatic Nonseminomatous Germ Cell Tumor
In a single-institution retrospective study reported in the Journal of Clinical Oncology, Taza et al found that the presence of teratoma in primary tumor and postchemotherapy retroperitoneal lymph node dissection specimens was not a prognostic factor in patients with metastatic testicular germ cell ...
QOPI Round 1 Now Open for Data Abstraction: Improve Quality Practice-Wide
ASCO’s Quality Oncology Practice Initiative (QOPI®) Round 1 of reporting is open for data abstraction. Round 1 will close on June 5, 2020, and final reports will be available approximately 4 weeks later. To get started, go to the registration portal at myqopi.asco.org/registration/login.aspx and...
Roles Are Reversed in ‘Personalized Medicine’ as Physicians Care for Parents With Cancer
As early-career oncologists, Rachna Shroff, MD, and Nina Shah, MD, offered patients a textbook bedside manner—personal interactions were limited, and emotions were rarely shared. “People talk about how, especially in oncology, the more you let [a patient] in, the more profoundly you feel losses,...
Conquer Cancer–Funded Researcher’s Pancreatic Cancer Study Highlighted in ASCO’s Clinical Cancer Advances 2020
The work of nine researchers who have previously received funding from Conquer Cancer is featured in ASCO’s Clinical Cancer Advances 2020. Visit CONQUER.ORG for more details. Advance of the Year: Refinement of Surgical Treatment At Massachusetts General Hospital, Janet Murphy, MD, is expanding...
Zelia M. Correa, MD, PhD, Joins Sylvester Comprehensive Cancer Center and Bascom Palmer Eye Institute
An expert in ocular oncology, Zelia M. Correa, MD, PhD, has joined Sylvester Comprehensive Cancer Center and Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine as Co-Director of the Ocular Oncology Service. Dr. Correa specializes in the diagnosis and treatment of eye...
Susan Band Horwitz, PhD, Named Recipient of 2020 Szent-Györgyi Prize
The National Foundation for Cancer Research (NFCR) recently announced that Susan Band Horwitz, PhD, has been selected to receive the 2020 Szent-Györgyi Prize for Progress in Cancer Research. Dr. Horwitz is being recognized for pioneering the understanding, at the molecular level, of the mechanisms...
Reflections on a Career in Hematology/Oncology
I am a retired 82-year-old Hematologist/Oncologist who reads The ASCO Post regularly. I am writing to share some brief thoughts with the authors of two articles in the February 10, 2020 issue. First, I would address the article, A Hopeful Look Ahead in Oncology, written by Dan L. Longo, MD, MACP....
Former ASCO President Sandra M. Swain, MD, FACP, FASCO, Shares Highlights of a Noted Career
In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Sandra M. Swain, MD, FACP, FASCO, Professor of Medicine and Associate Dean for Research Development at Georgetown University Medical Center, and Vice President of MedStar Genetic Medicine at Medstar...
Attempt to Transform Venipuncture: A Brilliant Idea Made From Smoke and Mirrors
Venipuncture is the most commonly performed invasive procedure in hospitals daily. The risk of this procedure is nerve damage or an arterial nick. Of course, there are other possible issues, such as hematoma and injection-site infection. Then there’s dealing with caterwauling children and swooning...
Tazemetostat for Advanced Epithelioid Sarcoma
On January 23, 2020, tazemetostat was granted accelerated approval for the treatment of adults and pediatric patients aged 16 and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.1,2 Supporting Efficacy Data Approval was based on the finding of...
Selected ASH Abstracts on Novel Treatments in Acute Lymphoblastic Leukemia
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for newly diagnosed and relapsed or refractory acute...
Avapritinib for Gastrointestinal Stromal Tumor With PDGFRA Exon 18 Mutation
On January 9, 2020, avapritinib was approved for treatment of adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including D842V mutations.1,2 It is the first therapy approved for...
21-Gene Assay Recurrence Score and Risk of Locoregional Recurrence in Hormone Receptor–Positive, Node-Positive Breast Cancer
A retrospective analysis from the Southwest Oncology Group S8814 trial, reported by Wendy A. Woodward, MD, PhD, of the Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, and colleagues in JAMA Oncology,1 showed that a low 21-gene assay recurrence score was...
Brief Highlights From the 2019 San Antonio Breast Cancer Symposium
In addition to our regular coverage of the 2019 San Antonio Breast Cancer Symposium, the following reports from the meeting include studies you may have missed. We hope you find them of interest. Ribociclib/Letrozole as Neoadjuvant Therapy As neoadjuvant therapy in women with high-risk hormone...
Hongchao Pan, PhD, on an Update on 5 Years of Endocrine Therapy for Early Breast Cancer
Hongchao Pan, PhD, of the University of Oxford, discusses an analysis of 86,000 women in the Early Breast Cancer Trialists’ Collaborative Group database, which showed that the risk of distant recurrence 20 years after a diagnosis of node-negative, estrogen receptor–negative early-stage breast...
H. Timothy Hsiao, PhD, Joins the American Society for Radiation Oncology as Director of Scientific Affairs
The American Society for Radiation Oncology (ASTRO) recently welcomed H. Timothy Hsiao, PhD, as its new Director of Scientific Affairs, where he will provide strategic leadership to advance the impact of research and innovation in radiation oncology through ASTRO’s research funding, fellowships,...
Oral Regimen of Ibrutinib/Venetoclax Achieves High Rates of Undetectable Minimal Residual Disease in CLL
Updated results of the phase II CAPTIVATE trial continue to show high response rates as well as high rates of undetectable minimal residual disease (MRD) with ibrutinib plus venetoclax as front-line treatment of chronic lymphocytic leukemia (CLL) in patients under the age of 70 years. The...
Treating Patients With Chronic Lymphocytic Leukemia in 2020
With the availability of a number of effective targeted agents for the treatment of chronic lymphocytic leukemia (CLL), the question arises whether chemotherapy still has a role in treating this malignancy. At the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, CLL...
Rush University Medical Center Earns National Center of Excellence for Pancreatic Cancer Designation
The National Pancreas Foundation has named Rush University Medical Center as a National Center of Excellence for Pancreatic Cancer, a designation given to hospitals that have demonstrated the multidisciplinary approach, social support, and advanced research resources needed to successfully treat...
Novel Combination of Cabozantinib Plus Atezolizumab Shows Benefit in Patients With Advanced Prostate Cancer
The combination of the small-molecule tyrosine kinase inhibitor cabozantinib (inhibits VEGF, AXL, MET, and others), plus the immune checkpoint inhibitor atezolizumab achieved encouraging activity in patients with metastatic castration-resistant prostate cancer, according to the results of...
ASCO’s TAPUR Study: Biomarker-Driven Treatment Paying Off in Colorectal Cancer
New data presented at the 2020 Gastrointestinal Cancers Symposium are validating the purpose of ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study, a multibasket trial that matches patients’ genomic alterations to commercially available targeted therapies. The aim is to learn...
Richard L. Schilsky, MD, FACP, FSCT, FASCO, Designated a National Associate of the National Academies of Sciences, Engineering, and Medicine
In February 2020, Richard L. Schilsky, MD, FACP, FSCT, FASCO, Chief Medical Officer and Executive Vice President of ASCO, was designated a National Associate of the National Academy of Sciences, Engineering, and Medicine for his decades-long contributions to the National Academy of Medicine (NAM). ...
An Education in Human Suffering
By way of tradition, our current system of oncology training exposes fellows to vast amounts of suffering in their first year. As fellows, we see dying patients with cancer in the hospital; we see the third-opinion, last-ditch referrals; we see most newly presenting patients; and we spend the hours ...
MK-6482 Shows Activity Across All Risk Categories in Metastatic Clear Cell Kidney Cancer
A novel approach using a drug called MK-6482 showed activity in a phase I/II study in patients with metastatic clear cell renal cell carcinoma, according to a presentation at the 2020 Genitourinary Cancers Symposium.1 MK-6482 is an oral, first-in-class selective small-molecule inhibitor that...
Expert on Public Health and Policy Looks at Precision Oncology
A study published in JAMA Oncology found that 31 genome-targeted anticancer agents were in use as of January 2018.1 To shed light on the current state of precision oncology, The ASCO Post recently spoke with David M. Cutler, PhD, the Otto Eckstein Professor of Applied Economics in the Department of ...
FDA Pipeline: Priority Review in DLBCL, Fast Track Designations in T-Cell Lymphoma and Adenoid Cystic Carcinoma
Over the past week, the U.S. Food and Drug Administration (FDA) granted Priority Review to a combination therapy in diffuse large B-cell lymphoma (DLBCL); gave Fast Track designations for treatments in T-cell lymphoma and adenoid cystic carcinoma; granted Orphan Drug designation to an agent for the ...
Young Women Diagnosed With Breast Cancer May Face Employment Disruption and Financial Hardship
A study evaluating the economic impact of the cancer in young women has found that the diagnosis can result in employment disruption and financial decline. The findings—published by Tangka et al in Cancer Epidemiology, Biomarkers & Prevention—indicate the need for obtaining and maintaining...
NSABP B-42 Trial 10-Year Update: Impact of Extended Letrozole on Disease-Free Survival
“In the 10-year analysis of the NSABP B-42 trial, the effect of extended treatment with 5 years of letrozole on disease-free survival persisted and reached statistical significance. There was no significant improvement in overall survival with letrozole, but letrozole continued to provide a...
Investigators in Brazil Explore Availability, Cost, and Use of Biosimilar Trastuzumab in Patients With HER2-Positive Breast Cancer
Investigators in Brazil are seeking to explore the efficacy and safety of adjuvant biosimilar trastuzumab in a real-world study of patients with early HER2-positive breast cancer. In 2019, biosimilar trastuzumab became the first biosimilar approved in Brazil for the treatment of patients with...
